VKTXViking Therapeutics, Inc.
Pharmaceutical Preparations
- Revenue
- $0
- Operating margin
- —
- EBITDA
- −$393M
- 161% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear—Over 10% of revenue
- Payouts exceed cash flowClear-2% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | |
| Operating income | −$56M | −$70M | −$101M | −$151M | −$393M | 161% |
| Net income | −$55M | −$69M | −$86M | −$110M | −$360M | 227% |
| Operating cash flow | −$48M | −$48M | −$73M | −$88M | −$279M | 217% |
| Stock-based comp | $6M | $9M | $17M | $30M | $41M | 37% |
| Buybacks | — | $7M | — | — | — |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
No pay-versus-performance disclosure yet.